Hospital Morphine Preparation for Abstinence Syndrome in Newborns Exposed to Buprenorphine or Methadone

Overview

Journal Pharm World Sci

Publisher Springer

Specialties Pharmacology
Pharmacy

Date 2007 Nov 17

PMID 18008179

Citations 12

Authors

Nathalie Colombini

Riad Elias

Muriel Busuttil

Myriam Dubuc

Marie-Ange Einaudi

Martine Bues-Charbit

Affiliations

Soon will be listed here.

Abstract

Objective: This study was undertaken to evaluate the adequacy of a hospital formulated oral morphine preparation for management of neonatal abstinence syndrome (NAS) and to compare clinical features in infants exposed to methadone or buprenorphine in utero.

Method: Between October 1998 and October 2004 all infants born to mothers treated with buprenorphine or methadone during pregnancy were enrolled into this prospective study. Morphine hydrochloride solution (0.2 mg/ml) was prepared without preservatives under a flow laminar air box (class 100).

Mean Outcome Measure: Morphine solution: quantitative and qualitative HPLC analysis and microbiological study at regular intervals during storage at 4 degrees C for 6 months. Maternal characteristics: age, opiate dose during pregnancy. Neonatal characteristics: gestational age at delivery, birth weight, Lipsitz scores. Morphine dose: daily morphine dose, maximum morphine dose, duration of NAS, and duration of treatment required to achieve stable Lipsitz scores below 4.

Statistics: Kruskal-Wallis test for comparison of median values.

Results: Microbiological and HPLC analysis showed that the morphine preparation remained stable for 6 months at 4 degrees C. Nine methadone-exposed infants and 13 buprenorphine-exposed infants were included in the study. All infants presented NAS requiring treatment with the morphine solution. Lipsitz scores at birth were significantly different in the methadone and buprenorphine groups (P < 0.05). The methadone group required significantly higher doses of morphine preparation than the buprenorphine group during the first 38 days of treatment (P < 0.05): 0.435 +/- 0.150 mg/kg/day vs. 0.257 +/- 0.083 mg/kg/day.

Conclusion: This hospital morphine solution is adequate for management of NAS. Preparations showed good stability and doses could be adjusted with a margin of 0.02 mg. The onset of NAS occurred within 24 h after birth in methadone-exposed infants (range 6-24 h) and within 48 h after birth in buprenorphine-exposed infants (range 24-168 h). Due to the possibility of delayed onset of NAS up to 7 days, infants born to mothers treated with buprenorphine should be kept in the hospital for an appropriate surveillance period. Treatment time was significantly longer (45 vs. 28 days) and the mean morphine doses were higher (1.7 fold) in methadone-exposed than buprenorphine-exposed infants.

Citing Articles

Neonatal Abstinence Syndrome in Infants with Prenatal Exposure to Methadone versus Buprenorphine.

Kushnir A, Bhavsar R, Hanna E, Hegyi T Children (Basel). 2023; 10(6).

PMID: 37371262 PMC: 10297113. DOI: 10.3390/children10061030.

Identifying the Neurodevelopmental Differences of Opioid Withdrawal.

van den Hoogen N, Kwok C, Trang T Cell Mol Neurobiol. 2021; 41(5):1145-1155.

PMID: 33432504 PMC: 11448592. DOI: 10.1007/s10571-020-01035-6.

Outcome reporting in neonates experiencing withdrawal following opioid exposure in pregnancy: a systematic review.

Shan F, MacVicar S, Allegaert K, Offringa M, Jansson L, Simpson S Trials. 2020; 21(1):262.

PMID: 32164782 PMC: 7069160. DOI: 10.1186/s13063-020-4183-9.

Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child.

Zedler B, Mann A, Kim M, Amick H, Joyce A, Murrelle E Addiction. 2016; 111(12):2115-2128.

PMID: 27223595 PMC: 5129590. DOI: 10.1111/add.13462.

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes.

Lund I, Fischer G, Welle-Strand G, OGrady K, Debelak K, Morrone W Subst Abuse. 2013; 7:61-74.

PMID: 23531704 PMC: 3603528. DOI: 10.4137/SART.S10955.

References

Levy M, Spino M . Neonatal withdrawal syndrome: associated drugs and pharmacologic management. Pharmacotherapy. 1993; 13(3):202-11. View

Sinha C, Ohadike P, Carrick P, Pairaudeau P, Armstrong D, Lindow S . Neonatal outcome following maternal opiate use in late pregnancy. Int J Gynaecol Obstet. 2001; 74(3):241-6. DOI: 10.1016/s0020-7292(01)00446-5. View

Jentile B, Elias R, Dejode J, Lagier P, Bues-Charbit M, Balansard G . Preparation and use of morphine capsules in paediatric patients with burns. J Pharm Belg. 1998; 52(6):217-8. View

Coyle M, Ferguson A, LaGasse L, Oh W, Lester B . Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002; 140(5):561-4. DOI: 10.1067/mpd.2002.123099. View

SUTTON L, Hinderliter S . Diazepam abuse in pregnant women on methadone maintenance. Implications for the neonate. Clin Pediatr (Phila). 1990; 29(2):108-11. DOI: 10.1177/000992289002900208. View

Tran J . Treatment of neonatal abstinence syndrome. J Pediatr Health Care. 2000; 13(6 Pt 1):295-300; quiz 301-2. DOI: 10.1016/s0891-5245(99)90023-8. View

. Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs. Pediatrics. 1998; 101(6):1079-88. View

Anderson I, Kearney T . Use of methadone. West J Med. 2000; 172(1):43-6. PMC: 1070723. DOI: 10.1136/ewjm.172.1.43. View

Kandall S, Gaines J . Maternal substance use and subsequent sudden infant death syndrome (SIDS) in offspring. Neurotoxicol Teratol. 1991; 13(2):235-40. DOI: 10.1016/0892-0362(91)90016-p. View

10.

Ferraro F, Ferraro R, Massard A . [Consequences of cocaine addiction during pregnancy on the development in the child]. Arch Pediatr. 1997; 4(7):677-82. DOI: 10.1016/s0929-693x(97)83373-8. View

11.

Coghlan D, Milner M, Clarke T, Lambert I, McDermott C, McNally M . Neonatal abstinence syndrome. Ir Med J. 1999; 92(1):232-3, 236. View

12.

Dashe J, Jackson G, Olscher D, Zane E, Wendel Jr G . Opioid detoxification in pregnancy. Obstet Gynecol. 1998; 92(5):854-8. DOI: 10.1016/s0029-7844(98)00312-3. View

13.

Jernite M, Viville B, Escande B, Brettes J, Messer J . [Buprenorphine and pregnancy. Analysis of 24 cases]. Arch Pediatr. 1999; 6(11):1179-85. DOI: 10.1016/S0929-693X(00)86300-9. View

14.

Lejeune C, Floch-Tudal C, Montamat S, Crenn-Hebert C, Simonpoli A . [Management of drug addict pregnant women and their children]. Arch Pediatr. 1997; 4(3):263-70. DOI: 10.1016/s0929-693x(97)87247-8. View

15.

Nanovskaya T, Deshmukh S, Brooks M, Ahmed M . Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther. 2001; 300(1):26-33. DOI: 10.1124/jpet.300.1.26. View

16.

Choo R, Huestis M, Schroeder J, Shin A, Jones H . Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend. 2004; 75(3):253-60. DOI: 10.1016/j.drugalcdep.2004.03.012. View

17.

Theis J, Selby P, Ikizler Y, Koren G . Current management of the neonatal abstinence syndrome: a critical analysis of the evidence. Biol Neonate. 1997; 71(6):345-56. DOI: 10.1159/000244435. View

18.

Regini P, Cutrone M, DONZELLI F, Flora P, Montesanto G . [Neonatal buprenorphine withdrawal syndrome, what is the right therapy?]. Pediatr Med Chir. 1998; 20(1):67-9. View

19.

Johnson R, Jones H, Fischer G . Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003; 70(2 Suppl):S87-101. DOI: 10.1016/s0376-8716(03)00062-0. View

20.

Johnson R, Jones H, Jasinski D, Svikis D, Haug N, Jansson L . Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 2001; 63(1):97-103. DOI: 10.1016/s0376-8716(00)00194-0. View